The Longevity Fund
VC · San Francisco · United States
Etapas
Región de inversión
Industrias
Perfil
The Longevity Fund is a venture capital firm based in San Francisco, founded in 2011 by Laura Deming. They focus on investing in companies that aim to increase the healthy lifespan of humans through medical advancements, particularly targeting age-related diseases. The firm is known for backing pioneering companies in the longevity field and continues to support mission-oriented entrepreneurs with a passion for this emerging sector. Their team is dedicated to scouting and nurturing talent that can drive groundbreaking developments in longevity medicine. The Longevity Fund invests in biotechnology, pharmaceuticals, and healthcare services, alongside other life sciences sectors. They focus on early-stage funding, primarily Series A, with investments typically ranging from $1-5 million. The firm operates globally but has a pronounced interest in companies with the potential to impact longevity sciences. They recently announced a new vehicle named the Age1 Fund, which will further explore innovative longevity solutions. Notable investments from The Longevity Fund include companies like Unity Biotechnology - focusing on therapies for age-related diseases, and Precision Biosciences - an early-stage company in genome editing. They are recognized for nurturing founders who challenge the norm in biotech to develop transformative products in the healthcare industry.
Contactos (2)
| Nombre | Cargo | Teléfono | ||
|---|---|---|---|---|
| Partner | — | — | — | |
| Head of Operations | — | — | — |
El nombre, email y teléfono se muestran en sombra. Suscribite para verlos completos.